Insulatard

A brand name for a slow acting INSULIN.

Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Mentioned in ?

References in periodicals archive ?

In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).

Human Insulin Market - Forecasts to 2020: New research report available at Fast Market Research

SC Isophane Insulin (insulatard)###anti-diabetic###8 units ON

END STAGE RENAL FAILURE WITH MULTIPLE CO-MORBIDITY

All the patients were treated with intensified insulin therapy, multiple daily (subcutaneous) injection, 4 daily doses, human rapid acting insulin (Actrapid HM 100, Novo Nordisk) before the meals and in the evening at bedtime, and NPH insulin (Insulatard HM 100, Novo Nordisk).

High risk first degree relatives of type 1 diabetics: an association with increases in [CXCR3.sup.+] T memory cells reflecting an enhanced activity of Th1 autoimmune response

Patients were randomly assigned to receive NPH insulin at bedtime (Insulatard; Novo Nordisk, Copenhagen, Denmark) in addition to current treatment with sulfonylurea and metformin (insulin combination [IC] group) or to receive a mixture of 30% soluble and 70% NPH insulin (Mixtard 30/70; Novo Nordisk, Copenhagen, Denmark), twice daily before breakfast and dinner (insulin monotherapy [IM] group).

Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care